A team of researchers in Australia and the United States has developed an experimental antiviral therapy, gene-silencing RNA, that can reduce the amount of neovirus (CCA virus) by 99.9%, which can improve the survival rate and mortality of infected rats. (Diagram/shutterstock)
A team of Australian and U.S. researchers has developed a new antiviral therapy, gene-silencing RNA technology, which can destroy 99.9% of the new coronavirus in rats.
The Australian and U.S. research team developed an experimental antiviral therapy that can reduce 99.9% of the amount of new coronavirus, the team is currently conducting experiments on rats, confirmed that it can improve the survival rate and mortality rate of rats, in the surviving rats, the lungs have been pinpointed no virus.
Comprehensive Australian financial media “Business News Australia”, the Australian Broadcasting Corporation (ABC) reported, by Australia Griffith University (Griffith University) affiliated with the Queensland Menzies Health Institute (Menzies Health Institute Queensland) A multinational team of researchers from the Menzies Health Institute Queensland and the Beckman Research Institute in the United States has published a new generation of antiviral therapies capable of destroying the new coronavirus in the international academic journal Molecular Therapy on the 13th.
The team used a gene-silencing RNA technique called small interfering RNA (siRNA) to directly attack the genome of the virus so that the virus can no longer replicate, and the team also made custom lipid nanoparticles to deliver small interfering RNA directly into the lungs of patients. The team has now conducted experiments on rats, says Nigel McMillan, co-lead researcher at Griffith University, “and the team injects the lipid nanoparticles and they seek out the virus on their own and then destroy it like a heat-seeking missile. missile) to destroy the virus.”
He said that this is the first time they can be wrapped into the form of particles sent into the blood vessels, attack the virus, small interfering RNA through the blood vessel delivery into the lungs, lung cells, destroy the virus-infected lung cells, this therapy reduces the amount of virus 99.9%, he also stressed that the treatment process, the general normal cells are not harmed at all.
Gene silent RNA technology is mainly built on top of existing antiviral drugs such as gram flu (Tamiflu), Ridciclovir (Remdesivir), etc. These drugs work mainly in reducing the symptoms of new crowns and allowing patients to recover sooner, but McMillan pointed out that the new technology can stop the virus from replicating, so patients can recover on their own, and this approach will also allow patients to recover faster.
McMillan noted that although the genetically silent RNA technology does not completely “cure” patients with neocon, it is almost as effective as a complete cure, in rat experiments, the team found that the surviving rats “have no detectable neocon virus in their lungs “The treatment improved the survival and mortality rates of the infected rats.”
He said the therapy can treat patients with severe disease or mild disease in quarantine centers, for which it is too late to vaccinate, and for the latter, the therapy can ensure that patients do not suffer from the disease, “if treated quickly enough, we can basically rule out people dying from the disease.”
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), has pointed out that although a vaccine for the new crown is currently on the market, there is still no direct treatment for the new crown virus, McMillan said, adding that as far as direct therapies go, gene silencing RNA technology is considered the first.
Another advantage of gene silencing RNA technology is that it is not only suitable for fighting neo-coronaviruses, but also for defeating variant neo-coronaviruses and even other species of coronaviruses. Professor Kevin Morris, co-author of the Griffith University study, said the therapy is designed to combat all subtypes of coronaviruses, including SARS coronavirus (SARS-CoV-1), novel coronavirus (SARS-CoV-2), and any future variants that develop, and said the technology primarily targets the ultraconserved regions of the viral genome The technique targets ultraconserved regions in the viral genome, he said.
In addition, the nanoparticles used in the therapy can remain stable for up to 12 months at 4 degrees Celsius and more than a month at room temperature, making it possible to treat patients with new coronas in this way in resource-poor settings.
McMillan said the team is next to conduct the next phase of clinical trials, and if things go well, the therapy could be performed on humans as early as 2023.
Recent Comments